董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Buckman | 男 | Director | 69 | 4.00万美元 | 4.84 | 2025-06-30 |
| Casey Tansey | 男 | Director | 67 | 未披露 | 269.31 | 2025-06-30 |
| Geoff Pardo | 男 | Director | 54 | 未披露 | 228.05 | 2025-06-30 |
| Kevin Sidow | 男 | Director | 67 | 5.81万美元 | 5.51 | 2025-06-30 |
| Robert Ball | 男 | Chief Executive Officer and Executive Chairman | 53 | 62.81万美元 | 45.91 | 2025-06-30 |
| Matthew Ahearn | 男 | Chief Operating Officer and Director | 56 | 未披露 | 22.87 | 2025-06-30 |
| Richard J. Buchholz | 男 | Director | 57 | 未披露 | 未持股 | 2025-06-30 |
| Michael Carusi | 男 | Director | 60 | 未披露 | 161.85 | 2025-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Ball | 男 | Chief Executive Officer and Executive Chairman | 53 | 62.81万美元 | 45.91 | 2025-06-30 |
| Jeffrey Points | 男 | Chief Financial Officer | 48 | 50.78万美元 | 8.84 | 2025-06-30 |
| Matthew Ahearn | 男 | Chief Operating Officer and Director | 56 | 未披露 | 22.87 | 2025-06-30 |
| David L. Blue | 男 | Chief Customer Experience Officer | 64 | 49.73万美元 | 13.89 | 2025-06-30 |
董事简历
中英对照 | 中文 | 英文- Paul Buckman
-
Paul Buckman目前是LivaNova PLC TMVR的总经理。在加入Livanova之前，Buckman先生于2013年9月至2017年3月担任Conventus Orthopaedics（一家位于明尼苏达州的公司，专门从事关节周围骨折固定）的首席执行官。Buckman从2012年2月到2013年9月担任SentreHeart，Inc.（一家医疗技术公司，专注于关闭各种解剖结构）首席执行官。此前，Buckman从2008年9月到2012年2月担任Pathway Medical Technologies，Inc.（一家医疗设备公司，专注于治疗外周动脉疾病）首席执行官和董事长；2006年12月至2008年9月；2004年8月至2006年12月，担任上市多元化医疗产品公司圣犹达医疗公司心脏病部总裁；以及EV3LLC董事会主席兼首席执行官，从2001年1月到2004年1月，Buckman先生创立了一家总部位于明尼苏达州的医疗器械公司，专注于血管内疗法，并将其发展成为一家价值8000万美元的企业。巴克曼先生在医疗设备行业工作了30多年，包括在SCIMED Life Systems，Inc.和波士顿科学国际有限公司（一家公开上市的医疗设备制造商）工作了10年，在那里他担任过几个执行职位，直到2000年1月成为波士顿科学公司心脏病部门的总裁。Buckman先生目前还担任NeuroOne，Inc.的董事。Chariman，Ablative Solutions，Inc.，Activortho，Aortica，Inc.，Dyamx，Inc.和MiroMatrix，Inc.（董事长）。他此前曾担任Conventus Orthopaedics公司、Caisson Interventional LLC、Velocimed公司的董事，在那里他曾担任Endicor公司、Microvena公司、Sunshine Heart公司（上市早期医疗设备公司）、Micro Therapeutics公司的联席创始人。除了筹集了超过5亿美元的私人资本外，巴克曼担任首席执行官、董事或联合创始人的公司的总退出价值约为28亿美元。Buckman先生在西密歇根大学（Western Michigan University）获得工商管理与财务硕士学位和工商管理学士学位。
Paul Buckman,has served as Chief Executive Officer of Rhythmlink International LLC. Mr. Buckman previously served as President of Advanced Circulatory Support for LivaNova PLC (Nasdaq: LIVN) and as President, North America and the general manager of structural heart for LivaNova PLC beginning in April 2017. Prior to joining LivaNova PLC, Mr. Buckman served as chief executive officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation, from September 2013 until March of 2017. Mr. Buckman was chief executive officer of Sentreheart, Inc., a medical technology company focused on closure of various anatomic structures, from February 2012 to September 2013. Previously, Mr. Buckman served as chief executive officer and chairman of Pathway Medical Technologies, Inc., a medical device company focused on treatment of peripheral arterial disease, from September 2008 to February 2012; as chief executive officer of Devax, Inc., a developer and manufacturer of drug eluting stents, from December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc., a publicly traded diversified medical products company, from August 2004 to December 2006; and as chairman of the board of directors and chief executive officer of ev3, LLC, a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman founded and developed into an $80 million business, from January 2001 to January 2004. Mr. Buckman has worked in the medical device industry for over 30 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation (NYSE: BSX), a publicly traded medical device manufacturer, where he held several executive positions before becoming president of the cardiology division of Boston Scientific in January 2000. Mr. Buckman also currently serves as a director for Helius Medical Technologies Corporation (Nasdaq: HSDT), Ablative Solutions, Inc., ActivOrtho Inc., a privately held company, Shoulder Innovations, Inc., a privately held company, Rhythmlink International LLC, a privately held company, and as chairman of Miromatrix, Inc. He previously served as a director of Aortica, Inc., DyaMX, Inc., Conventus Orthopaedics, Caisson Interventional LLC, Velocimed, Inc., where he was a co-founder, EndiCor, Inc., Microvena, Inc., Sunshine Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company, NexGen Medical, and Micro Therapeutics, Inc. Mr. Buckman received a Master's degree in Business Administration and Finance and a B.A. degree in Business Administration from Western Michigan University. - Paul Buckman目前是LivaNova PLC TMVR的总经理。在加入Livanova之前，Buckman先生于2013年9月至2017年3月担任Conventus Orthopaedics（一家位于明尼苏达州的公司，专门从事关节周围骨折固定）的首席执行官。Buckman从2012年2月到2013年9月担任SentreHeart，Inc.（一家医疗技术公司，专注于关闭各种解剖结构）首席执行官。此前，Buckman从2008年9月到2012年2月担任Pathway Medical Technologies，Inc.（一家医疗设备公司，专注于治疗外周动脉疾病）首席执行官和董事长；2006年12月至2008年9月；2004年8月至2006年12月，担任上市多元化医疗产品公司圣犹达医疗公司心脏病部总裁；以及EV3LLC董事会主席兼首席执行官，从2001年1月到2004年1月，Buckman先生创立了一家总部位于明尼苏达州的医疗器械公司，专注于血管内疗法，并将其发展成为一家价值8000万美元的企业。巴克曼先生在医疗设备行业工作了30多年，包括在SCIMED Life Systems，Inc.和波士顿科学国际有限公司（一家公开上市的医疗设备制造商）工作了10年，在那里他担任过几个执行职位，直到2000年1月成为波士顿科学公司心脏病部门的总裁。Buckman先生目前还担任NeuroOne，Inc.的董事。Chariman，Ablative Solutions，Inc.，Activortho，Aortica，Inc.，Dyamx，Inc.和MiroMatrix，Inc.（董事长）。他此前曾担任Conventus Orthopaedics公司、Caisson Interventional LLC、Velocimed公司的董事，在那里他曾担任Endicor公司、Microvena公司、Sunshine Heart公司（上市早期医疗设备公司）、Micro Therapeutics公司的联席创始人。除了筹集了超过5亿美元的私人资本外，巴克曼担任首席执行官、董事或联合创始人的公司的总退出价值约为28亿美元。Buckman先生在西密歇根大学（Western Michigan University）获得工商管理与财务硕士学位和工商管理学士学位。
- Paul Buckman,has served as Chief Executive Officer of Rhythmlink International LLC. Mr. Buckman previously served as President of Advanced Circulatory Support for LivaNova PLC (Nasdaq: LIVN) and as President, North America and the general manager of structural heart for LivaNova PLC beginning in April 2017. Prior to joining LivaNova PLC, Mr. Buckman served as chief executive officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation, from September 2013 until March of 2017. Mr. Buckman was chief executive officer of Sentreheart, Inc., a medical technology company focused on closure of various anatomic structures, from February 2012 to September 2013. Previously, Mr. Buckman served as chief executive officer and chairman of Pathway Medical Technologies, Inc., a medical device company focused on treatment of peripheral arterial disease, from September 2008 to February 2012; as chief executive officer of Devax, Inc., a developer and manufacturer of drug eluting stents, from December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc., a publicly traded diversified medical products company, from August 2004 to December 2006; and as chairman of the board of directors and chief executive officer of ev3, LLC, a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman founded and developed into an $80 million business, from January 2001 to January 2004. Mr. Buckman has worked in the medical device industry for over 30 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation (NYSE: BSX), a publicly traded medical device manufacturer, where he held several executive positions before becoming president of the cardiology division of Boston Scientific in January 2000. Mr. Buckman also currently serves as a director for Helius Medical Technologies Corporation (Nasdaq: HSDT), Ablative Solutions, Inc., ActivOrtho Inc., a privately held company, Shoulder Innovations, Inc., a privately held company, Rhythmlink International LLC, a privately held company, and as chairman of Miromatrix, Inc. He previously served as a director of Aortica, Inc., DyaMX, Inc., Conventus Orthopaedics, Caisson Interventional LLC, Velocimed, Inc., where he was a co-founder, EndiCor, Inc., Microvena, Inc., Sunshine Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company, NexGen Medical, and Micro Therapeutics, Inc. Mr. Buckman received a Master's degree in Business Administration and Finance and a B.A. degree in Business Administration from Western Michigan University.
- Casey Tansey
-
Casey Tansey自2008年1月以来一直担任我们的董事会成员。Tansey先生自2014年8月起担任风险投资公司U.S.Venture Partners“；USVP”；的管理合伙人，并于2005年4月至2014年7月担任USVP的管理成员。Tansey先生曾于2006年至2017年担任IntersectEnt，Inc.董事会成员，并于2008年10月至2017年10月担任ReShape Medical，Inc.董事会成员。Tansey先生拥有圣母学院（College of Notre Dame）的学士学位和工商管理硕士学位。
Casey Tansey,has served on Shoulder Innovations board of directors since October 2020. Since 2014, Mr. Tansey has served as the Managing Partner of USVP Management Company. Mr. Tansey has been a member of the board of directors of Inspire Medical Systems, Inc.(NYSE: INSP) since 2007 and of UCSF MTVP Investment Advisory since 2017. He has also served on the boards of several other medical technology and healthcare-related companies, including Cagent Vascular, HeartFlow, Inc., Highlife Medical, Inc., Luminopia, Inc., MicroTransponder, Inc., Neuros Medical, NeoChord, Inc., and ShiraTronics. He received a B.S. in Business and a M.B.A. in Business from the College of Notre Dame. - Casey Tansey自2008年1月以来一直担任我们的董事会成员。Tansey先生自2014年8月起担任风险投资公司U.S.Venture Partners“；USVP”；的管理合伙人，并于2005年4月至2014年7月担任USVP的管理成员。Tansey先生曾于2006年至2017年担任IntersectEnt，Inc.董事会成员，并于2008年10月至2017年10月担任ReShape Medical，Inc.董事会成员。Tansey先生拥有圣母学院（College of Notre Dame）的学士学位和工商管理硕士学位。
- Casey Tansey,has served on Shoulder Innovations board of directors since October 2020. Since 2014, Mr. Tansey has served as the Managing Partner of USVP Management Company. Mr. Tansey has been a member of the board of directors of Inspire Medical Systems, Inc.(NYSE: INSP) since 2007 and of UCSF MTVP Investment Advisory since 2017. He has also served on the boards of several other medical technology and healthcare-related companies, including Cagent Vascular, HeartFlow, Inc., Highlife Medical, Inc., Luminopia, Inc., MicroTransponder, Inc., Neuros Medical, NeoChord, Inc., and ShiraTronics. He received a B.S. in Business and a M.B.A. in Business from the College of Notre Dame.
- Geoff Pardo
-
Geoff Pardo自2020年7月以来一直担任我们的董事会成员。Pardo先生自2011年以来一直担任Gilde梦百合的合伙人。此前，他曾担任Spray Venture Partners公司的合伙人（2004年至2011年）。他也曾担任Facet Solutions公司（脊柱植入公司，专注于治疗腰椎管狭窄症）的总裁兼首席执行官（从2007年到2011年公司出售给Globus Medical公司）。他目前担任以下上市医疗设备公司的董事会成员:InariMedical，Inc.和Vapotherm，Inc.他曾任职于以下上市公司的董事会:Axonics ModulationTechnologies，Inc.公司（医疗设备公司）。Pardo先生在布朗大学（Brown University）获得文学学士学位，并在沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
Geoff Pardo,has served as a member of Shoulder Innovations board of directors since February 2023. Since June 2011, he has also served as the President and General Partner of Gilde Healthcare US Inc. Concurrently, he serves on the boards of Nalu Medical, Mainstay Medical Holding plc, Ablative Solutions Inc., GT Medical Technologies, Inc. and Alleviant Medical. Previously, Mr. Pardo also served on the board of directors, including various committees, for several public and formerly public companies, including Inari Medical Inc. from March 2018 to May 2021, Axonics Inc. (Nasdaq: AXNX) from July 2017 to April 2019, Eargo Inc. (Nasdaq: EAR) from July 2020 to July 2021, Vapotherm, Inc. from March 2014 to October 2020 and CVRx Inc. (Nasdaq: CVRX) from August 2016 to June 2022. He received a B.A. from Brown University and an M.B.A from The Wharton School of Business. - Geoff Pardo自2020年7月以来一直担任我们的董事会成员。Pardo先生自2011年以来一直担任Gilde梦百合的合伙人。此前，他曾担任Spray Venture Partners公司的合伙人（2004年至2011年）。他也曾担任Facet Solutions公司（脊柱植入公司，专注于治疗腰椎管狭窄症）的总裁兼首席执行官（从2007年到2011年公司出售给Globus Medical公司）。他目前担任以下上市医疗设备公司的董事会成员:InariMedical，Inc.和Vapotherm，Inc.他曾任职于以下上市公司的董事会:Axonics ModulationTechnologies，Inc.公司（医疗设备公司）。Pardo先生在布朗大学（Brown University）获得文学学士学位，并在沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
- Geoff Pardo,has served as a member of Shoulder Innovations board of directors since February 2023. Since June 2011, he has also served as the President and General Partner of Gilde Healthcare US Inc. Concurrently, he serves on the boards of Nalu Medical, Mainstay Medical Holding plc, Ablative Solutions Inc., GT Medical Technologies, Inc. and Alleviant Medical. Previously, Mr. Pardo also served on the board of directors, including various committees, for several public and formerly public companies, including Inari Medical Inc. from March 2018 to May 2021, Axonics Inc. (Nasdaq: AXNX) from July 2017 to April 2019, Eargo Inc. (Nasdaq: EAR) from July 2020 to July 2021, Vapotherm, Inc. from March 2014 to October 2020 and CVRx Inc. (Nasdaq: CVRX) from August 2016 to June 2022. He received a B.A. from Brown University and an M.B.A from The Wharton School of Business.
- Kevin Sidow
-
Kevin Sidow，自2020年12月起担任CarlSMed，Inc.董事会成员。此前，Sidow先生在2008年2月至2017年7月退休期间担任私营医疗设备公司Moximed，Inc.的总裁兼首席执行官。在担任Moximed，Inc.总裁兼首席执行官之前，他曾于2004年5月至2007年5月担任2007年1月收购的脊柱植入物公司St. Francis Medical Technologies，Inc.的总裁兼首席执行官。Sidow先生目前在另一家医疗保健行业私营公司的董事会任职。Sidow先生获得了西弗吉尼亚大学会计学学士学位。
Kevin Sidow,has served as a member of Board of Directors since December 2020. Previously, Mr. Sidow was President and Chief Executive Officer of Moximed, Inc., a privately held medical device company, from February 2008 until his retirement in July 2017. Prior to serving as President and Chief Executive Officer of Moximed, Inc., he was President and Chief Executive Officer of St. Francis Medical Technologies, Inc., a spinal implant company acquired in January 2007, from May 2004 until May 2007. Mr. Sidow currently serves on the board of directors of another private company in the healthcare industry. Mr. Sidow received a B.S. in accounting from West Virginia University. - Kevin Sidow，自2020年12月起担任CarlSMed，Inc.董事会成员。此前，Sidow先生在2008年2月至2017年7月退休期间担任私营医疗设备公司Moximed，Inc.的总裁兼首席执行官。在担任Moximed，Inc.总裁兼首席执行官之前，他曾于2004年5月至2007年5月担任2007年1月收购的脊柱植入物公司St. Francis Medical Technologies，Inc.的总裁兼首席执行官。Sidow先生目前在另一家医疗保健行业私营公司的董事会任职。Sidow先生获得了西弗吉尼亚大学会计学学士学位。
- Kevin Sidow,has served as a member of Board of Directors since December 2020. Previously, Mr. Sidow was President and Chief Executive Officer of Moximed, Inc., a privately held medical device company, from February 2008 until his retirement in July 2017. Prior to serving as President and Chief Executive Officer of Moximed, Inc., he was President and Chief Executive Officer of St. Francis Medical Technologies, Inc., a spinal implant company acquired in January 2007, from May 2004 until May 2007. Mr. Sidow currently serves on the board of directors of another private company in the healthcare industry. Mr. Sidow received a B.S. in accounting from West Virginia University.
- Robert Ball
-
Robert Ball，自2020年10月起担任Shoulder Innovations首席执行官，自2015年4月起担任Shoulder Innovations董事会执行主席。在加入Shoulder Innovations之前，Ball先生是IMASCAP SA的负责人，该公司是一家私营软件公司，专注于肩关节置换术的术前规划，从2013年7月到2017年被Wright Medical Group, Inc.（现史赛克公司（NYSE：SYK））收购。在此之前，Ball先生曾于2006年8月至2013年12月在Tornier NV（一家全球骨科公司）任职，该公司被Wright Medical Group, Inc.（现史赛克公司）收购，任职于研发、监管和临床副总裁。鲍尔此前还曾在Kinetikos Medical Inc.（一家专注于骨科植入物的私营公司）和DEPUY（强生（纽约证券交易所代码：JNJ）的骨科公司任职。自2013年1月成立以来，他一直担任创世纪创新的董事长，创世纪创新是一家专注于早期医疗器械投资和开发的公司。Ball先生目前担任Genesis Innovation、Genesis Software、Genesis Investment Holdings、NSite LLC、Strados Labs LLC和Cultivation（MD）Holdings，LLC的董事。Ball先生获得了凯特林大学机械工程理学学士学位和机械工程理学硕士学位。
Robert Ball,has served as Shoulder Innovations Chief Executive Officer since October 2020 and as Shoulder Innovations executive chairman of the board of directors since April 2015. Prior to joining Shoulder Innovations, Mr. Ball was a Principal at Imascap SA, a privately-held software company focusing on preoperative planning for shoulder arthroplasty, from July 2013 until its acquisition by Wright Medical Group, Inc. (now Stryker Corporation (NYSE: SYK)) in 2017. Prior to this, Mr. Ball held positions at Tornier NV, a global orthopedics company that was acquired by Wright Medical Group, Inc. (now Stryker Corporation), from August 2006 to December 2013, including Vice President, Research & Development, Regulatory and Clinical. Mr. Ball also previously held positions at Kinetikos Medical Inc., a privately-held company focusing on orthopedic implants, and DePuy, the Orthopaedics Company of Johnson & Johnson (NYSE: JNJ). Since its inception in January 2013, he has served as Chairman of Genesis Innovation, a company focused on early-stage medical device investing and development. Mr. Ball currently serves as a director for Genesis Innovation, Genesis Software, Genesis Investment Holdings, NSite LLC, Strados Labs LLC, and cultivate(MD) Holdings, LLC. Mr. Ball received a Bachelor of Science in Mechanical Engineering and a Master of Science in Mechanical Engineering from Kettering University. - Robert Ball，自2020年10月起担任Shoulder Innovations首席执行官，自2015年4月起担任Shoulder Innovations董事会执行主席。在加入Shoulder Innovations之前，Ball先生是IMASCAP SA的负责人，该公司是一家私营软件公司，专注于肩关节置换术的术前规划，从2013年7月到2017年被Wright Medical Group, Inc.（现史赛克公司（NYSE：SYK））收购。在此之前，Ball先生曾于2006年8月至2013年12月在Tornier NV（一家全球骨科公司）任职，该公司被Wright Medical Group, Inc.（现史赛克公司）收购，任职于研发、监管和临床副总裁。鲍尔此前还曾在Kinetikos Medical Inc.（一家专注于骨科植入物的私营公司）和DEPUY（强生（纽约证券交易所代码：JNJ）的骨科公司任职。自2013年1月成立以来，他一直担任创世纪创新的董事长，创世纪创新是一家专注于早期医疗器械投资和开发的公司。Ball先生目前担任Genesis Innovation、Genesis Software、Genesis Investment Holdings、NSite LLC、Strados Labs LLC和Cultivation（MD）Holdings，LLC的董事。Ball先生获得了凯特林大学机械工程理学学士学位和机械工程理学硕士学位。
- Robert Ball,has served as Shoulder Innovations Chief Executive Officer since October 2020 and as Shoulder Innovations executive chairman of the board of directors since April 2015. Prior to joining Shoulder Innovations, Mr. Ball was a Principal at Imascap SA, a privately-held software company focusing on preoperative planning for shoulder arthroplasty, from July 2013 until its acquisition by Wright Medical Group, Inc. (now Stryker Corporation (NYSE: SYK)) in 2017. Prior to this, Mr. Ball held positions at Tornier NV, a global orthopedics company that was acquired by Wright Medical Group, Inc. (now Stryker Corporation), from August 2006 to December 2013, including Vice President, Research & Development, Regulatory and Clinical. Mr. Ball also previously held positions at Kinetikos Medical Inc., a privately-held company focusing on orthopedic implants, and DePuy, the Orthopaedics Company of Johnson & Johnson (NYSE: JNJ). Since its inception in January 2013, he has served as Chairman of Genesis Innovation, a company focused on early-stage medical device investing and development. Mr. Ball currently serves as a director for Genesis Innovation, Genesis Software, Genesis Investment Holdings, NSite LLC, Strados Labs LLC, and cultivate(MD) Holdings, LLC. Mr. Ball received a Bachelor of Science in Mechanical Engineering and a Master of Science in Mechanical Engineering from Kettering University.
- Matthew Ahearn
-
Matthew Ahearn，自2020年10月起担任Shoulder Innovations首席运营官，自2017年2月起担任Shoulder Innovations董事会成员。在担任此职务之前，Ahearn先生于2017年2月至2020年10月担任Shoulder Innovations首席执行官兼总裁，于2020年11月至2023年9月担任Shoulder Innovations 首席财务官兼首席运营官。Ahearn先生目前还担任HAPPE Spine，LLC、SpinTech MRI，Inc.、CPD to SPD，LLC、Culture（MD）Holdings，LLC和Genesis Investment Holdings的董事。他在阿尔比恩学院获得经济和管理文学士学位。
Matthew Ahearn,has served as Shoulder Innovations Chief Operating Officer since October 2020 and a member of Shoulder Innovations board of directors since February 2017. Prior to this role, Mr. Ahearn was Shoulder Innovations Chief Executive Officer and President from February 2017 to October 2020 and Shoulder Innovations Chief Financial Officer and Chief Operating Officer from November 2020 to September 2023. Mr. Ahearn also currently serves as a director for HAPPE Spine, LLC, SpinTech MRI, Inc., CPD to SPD, LLC, cultivate(MD) Holdings, LLC, and Genesis Investment Holdings. He received a Bachelor of Arts in Economics and Management from Albion College. - Matthew Ahearn，自2020年10月起担任Shoulder Innovations首席运营官，自2017年2月起担任Shoulder Innovations董事会成员。在担任此职务之前，Ahearn先生于2017年2月至2020年10月担任Shoulder Innovations首席执行官兼总裁，于2020年11月至2023年9月担任Shoulder Innovations 首席财务官兼首席运营官。Ahearn先生目前还担任HAPPE Spine，LLC、SpinTech MRI，Inc.、CPD to SPD，LLC、Culture（MD）Holdings，LLC和Genesis Investment Holdings的董事。他在阿尔比恩学院获得经济和管理文学士学位。
- Matthew Ahearn,has served as Shoulder Innovations Chief Operating Officer since October 2020 and a member of Shoulder Innovations board of directors since February 2017. Prior to this role, Mr. Ahearn was Shoulder Innovations Chief Executive Officer and President from February 2017 to October 2020 and Shoulder Innovations Chief Financial Officer and Chief Operating Officer from November 2020 to September 2023. Mr. Ahearn also currently serves as a director for HAPPE Spine, LLC, SpinTech MRI, Inc., CPD to SPD, LLC, cultivate(MD) Holdings, LLC, and Genesis Investment Holdings. He received a Bachelor of Arts in Economics and Management from Albion College.
- Richard J. Buchholz
-
Richard J. Buchholz，自2014年起担任Inspire Medical Systems, Inc.（NYSE：INSP）的首席财务官。在担任该职务之前，Buchholz先生于2006年至2013年期间担任医疗设备制造商SuperDimension，Ltd.（该公司于2012年被Covidien plc收购）的首席财务官、秘书和财务主管。Buchholz先生拥有威斯康星大学欧克莱尔分校的学士学位，是一名注册会计师（非在职）。
Richard J. Buchholz,has served as Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE: INSP) since 2014. Prior to that role, Mr. Buchholz served as the Chief Financial Officer, Secretary and Treasurer of superDimension, Ltd., a medical device manufacturer (which was acquired by Covidien plc in 2012), from 2006 to 2013. Mr. Buchholz holds a B.B.A from the University of Wisconsin, Eau Claire and is a Certified Public Accountant (inactive). - Richard J. Buchholz，自2014年起担任Inspire Medical Systems, Inc.（NYSE：INSP）的首席财务官。在担任该职务之前，Buchholz先生于2006年至2013年期间担任医疗设备制造商SuperDimension，Ltd.（该公司于2012年被Covidien plc收购）的首席财务官、秘书和财务主管。Buchholz先生拥有威斯康星大学欧克莱尔分校的学士学位，是一名注册会计师（非在职）。
- Richard J. Buchholz,has served as Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE: INSP) since 2014. Prior to that role, Mr. Buchholz served as the Chief Financial Officer, Secretary and Treasurer of superDimension, Ltd., a medical device manufacturer (which was acquired by Covidien plc in 2012), from 2006 to 2013. Mr. Buchholz holds a B.B.A from the University of Wisconsin, Eau Claire and is a Certified Public Accountant (inactive).
- Michael Carusi
-
Michael Carusi自1998年10月起担任风险投资公司Advanced Technology Ventures的普通合伙人。Carusi先生担任GI Dynamics的董事会成员，该公司在澳大利亚证券交易所上市。Carusi先生还曾在XTENT，Inc.的董事会任职，该公司在2009年之前都是一家上市公司。此外，他还在其他几家私营生命科学和医疗器械公司的董事会、审计委员会和薪酬委员会任职。Carusi先生获得利哈伊大学机械工程学士学位和达特茅斯学院阿莫斯·塔克商学院工商管理硕士学位。
Michael Carusi has served as a General Partner at Advanced Technology Ventures, a venture capital firm, since October 1998. Mr. Carusi serves on the board of directors of GI Dynamics, which is listed on the Australian Securities Exchange. Mr. Carusi has also served on the board of XTENT, Inc., which was a public company until 2009. In addition, he serves on the boards, audit committees and compensation committees of several other privately-held life sciences and medical device companies. Mr. Carusi received a B.S. degree in Mechanical Engineering from Lehigh University and an M.B.A. degree from the Amos Tuck School of Business at Dartmouth College. - Michael Carusi自1998年10月起担任风险投资公司Advanced Technology Ventures的普通合伙人。Carusi先生担任GI Dynamics的董事会成员，该公司在澳大利亚证券交易所上市。Carusi先生还曾在XTENT，Inc.的董事会任职，该公司在2009年之前都是一家上市公司。此外，他还在其他几家私营生命科学和医疗器械公司的董事会、审计委员会和薪酬委员会任职。Carusi先生获得利哈伊大学机械工程学士学位和达特茅斯学院阿莫斯·塔克商学院工商管理硕士学位。
- Michael Carusi has served as a General Partner at Advanced Technology Ventures, a venture capital firm, since October 1998. Mr. Carusi serves on the board of directors of GI Dynamics, which is listed on the Australian Securities Exchange. Mr. Carusi has also served on the board of XTENT, Inc., which was a public company until 2009. In addition, he serves on the boards, audit committees and compensation committees of several other privately-held life sciences and medical device companies. Mr. Carusi received a B.S. degree in Mechanical Engineering from Lehigh University and an M.B.A. degree from the Amos Tuck School of Business at Dartmouth College.
高管简历
中英对照 | 中文 | 英文- Robert Ball
Robert Ball，自2020年10月起担任Shoulder Innovations首席执行官，自2015年4月起担任Shoulder Innovations董事会执行主席。在加入Shoulder Innovations之前，Ball先生是IMASCAP SA的负责人，该公司是一家私营软件公司，专注于肩关节置换术的术前规划，从2013年7月到2017年被Wright Medical Group, Inc.（现史赛克公司（NYSE：SYK））收购。在此之前，Ball先生曾于2006年8月至2013年12月在Tornier NV（一家全球骨科公司）任职，该公司被Wright Medical Group, Inc.（现史赛克公司）收购，任职于研发、监管和临床副总裁。鲍尔此前还曾在Kinetikos Medical Inc.（一家专注于骨科植入物的私营公司）和DEPUY（强生（纽约证券交易所代码：JNJ）的骨科公司任职。自2013年1月成立以来，他一直担任创世纪创新的董事长，创世纪创新是一家专注于早期医疗器械投资和开发的公司。Ball先生目前担任Genesis Innovation、Genesis Software、Genesis Investment Holdings、NSite LLC、Strados Labs LLC和Cultivation（MD）Holdings，LLC的董事。Ball先生获得了凯特林大学机械工程理学学士学位和机械工程理学硕士学位。
Robert Ball,has served as Shoulder Innovations Chief Executive Officer since October 2020 and as Shoulder Innovations executive chairman of the board of directors since April 2015. Prior to joining Shoulder Innovations, Mr. Ball was a Principal at Imascap SA, a privately-held software company focusing on preoperative planning for shoulder arthroplasty, from July 2013 until its acquisition by Wright Medical Group, Inc. (now Stryker Corporation (NYSE: SYK)) in 2017. Prior to this, Mr. Ball held positions at Tornier NV, a global orthopedics company that was acquired by Wright Medical Group, Inc. (now Stryker Corporation), from August 2006 to December 2013, including Vice President, Research & Development, Regulatory and Clinical. Mr. Ball also previously held positions at Kinetikos Medical Inc., a privately-held company focusing on orthopedic implants, and DePuy, the Orthopaedics Company of Johnson & Johnson (NYSE: JNJ). Since its inception in January 2013, he has served as Chairman of Genesis Innovation, a company focused on early-stage medical device investing and development. Mr. Ball currently serves as a director for Genesis Innovation, Genesis Software, Genesis Investment Holdings, NSite LLC, Strados Labs LLC, and cultivate(MD) Holdings, LLC. Mr. Ball received a Bachelor of Science in Mechanical Engineering and a Master of Science in Mechanical Engineering from Kettering University.- Robert Ball，自2020年10月起担任Shoulder Innovations首席执行官，自2015年4月起担任Shoulder Innovations董事会执行主席。在加入Shoulder Innovations之前，Ball先生是IMASCAP SA的负责人，该公司是一家私营软件公司，专注于肩关节置换术的术前规划，从2013年7月到2017年被Wright Medical Group, Inc.（现史赛克公司（NYSE：SYK））收购。在此之前，Ball先生曾于2006年8月至2013年12月在Tornier NV（一家全球骨科公司）任职，该公司被Wright Medical Group, Inc.（现史赛克公司）收购，任职于研发、监管和临床副总裁。鲍尔此前还曾在Kinetikos Medical Inc.（一家专注于骨科植入物的私营公司）和DEPUY（强生（纽约证券交易所代码：JNJ）的骨科公司任职。自2013年1月成立以来，他一直担任创世纪创新的董事长，创世纪创新是一家专注于早期医疗器械投资和开发的公司。Ball先生目前担任Genesis Innovation、Genesis Software、Genesis Investment Holdings、NSite LLC、Strados Labs LLC和Cultivation（MD）Holdings，LLC的董事。Ball先生获得了凯特林大学机械工程理学学士学位和机械工程理学硕士学位。
- Robert Ball,has served as Shoulder Innovations Chief Executive Officer since October 2020 and as Shoulder Innovations executive chairman of the board of directors since April 2015. Prior to joining Shoulder Innovations, Mr. Ball was a Principal at Imascap SA, a privately-held software company focusing on preoperative planning for shoulder arthroplasty, from July 2013 until its acquisition by Wright Medical Group, Inc. (now Stryker Corporation (NYSE: SYK)) in 2017. Prior to this, Mr. Ball held positions at Tornier NV, a global orthopedics company that was acquired by Wright Medical Group, Inc. (now Stryker Corporation), from August 2006 to December 2013, including Vice President, Research & Development, Regulatory and Clinical. Mr. Ball also previously held positions at Kinetikos Medical Inc., a privately-held company focusing on orthopedic implants, and DePuy, the Orthopaedics Company of Johnson & Johnson (NYSE: JNJ). Since its inception in January 2013, he has served as Chairman of Genesis Innovation, a company focused on early-stage medical device investing and development. Mr. Ball currently serves as a director for Genesis Innovation, Genesis Software, Genesis Investment Holdings, NSite LLC, Strados Labs LLC, and cultivate(MD) Holdings, LLC. Mr. Ball received a Bachelor of Science in Mechanical Engineering and a Master of Science in Mechanical Engineering from Kettering University.
- Jeffrey Points
Jeffrey Points，自2023年9月起担任Sholder Innovations 首席财务官。在加入肩膀创新公司之前，Points先生曾于2007年至2023年在开发治疗外周和冠状动脉疾病解决方案的医疗设备公司Cardiovascular Systems, Inc.（纳斯达克：首席财务官）工作，曾担任多个职务，最近于2018年至2023年担任TERM3。Points先生获得了圣托马斯大学的工商管理硕士学位和伯特利大学的金融和会计学商业学士学位。
Jeffrey Points,has served as Shoulder Innovations Chief Financial Officer since September 2023. Prior to joining Shoulder Innovations, Mr. Points worked at Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company that developed solutions for treating peripheral and coronary artery disease, from 2007 to 2023, where he held various roles, including most recently as Chief Financial Officer from 2018 to 2023. Mr. Points received an M.B.A. from the University of St. Thomas and a B.A. in Business focusing on Finance and Accounting from Bethel University.- Jeffrey Points，自2023年9月起担任Sholder Innovations 首席财务官。在加入肩膀创新公司之前，Points先生曾于2007年至2023年在开发治疗外周和冠状动脉疾病解决方案的医疗设备公司Cardiovascular Systems, Inc.（纳斯达克：首席财务官）工作，曾担任多个职务，最近于2018年至2023年担任TERM3。Points先生获得了圣托马斯大学的工商管理硕士学位和伯特利大学的金融和会计学商业学士学位。
- Jeffrey Points,has served as Shoulder Innovations Chief Financial Officer since September 2023. Prior to joining Shoulder Innovations, Mr. Points worked at Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company that developed solutions for treating peripheral and coronary artery disease, from 2007 to 2023, where he held various roles, including most recently as Chief Financial Officer from 2018 to 2023. Mr. Points received an M.B.A. from the University of St. Thomas and a B.A. in Business focusing on Finance and Accounting from Bethel University.
- Matthew Ahearn
Matthew Ahearn，自2020年10月起担任Shoulder Innovations首席运营官，自2017年2月起担任Shoulder Innovations董事会成员。在担任此职务之前，Ahearn先生于2017年2月至2020年10月担任Shoulder Innovations首席执行官兼总裁，于2020年11月至2023年9月担任Shoulder Innovations 首席财务官兼首席运营官。Ahearn先生目前还担任HAPPE Spine，LLC、SpinTech MRI，Inc.、CPD to SPD，LLC、Culture（MD）Holdings，LLC和Genesis Investment Holdings的董事。他在阿尔比恩学院获得经济和管理文学士学位。
Matthew Ahearn,has served as Shoulder Innovations Chief Operating Officer since October 2020 and a member of Shoulder Innovations board of directors since February 2017. Prior to this role, Mr. Ahearn was Shoulder Innovations Chief Executive Officer and President from February 2017 to October 2020 and Shoulder Innovations Chief Financial Officer and Chief Operating Officer from November 2020 to September 2023. Mr. Ahearn also currently serves as a director for HAPPE Spine, LLC, SpinTech MRI, Inc., CPD to SPD, LLC, cultivate(MD) Holdings, LLC, and Genesis Investment Holdings. He received a Bachelor of Arts in Economics and Management from Albion College.- Matthew Ahearn，自2020年10月起担任Shoulder Innovations首席运营官，自2017年2月起担任Shoulder Innovations董事会成员。在担任此职务之前，Ahearn先生于2017年2月至2020年10月担任Shoulder Innovations首席执行官兼总裁，于2020年11月至2023年9月担任Shoulder Innovations 首席财务官兼首席运营官。Ahearn先生目前还担任HAPPE Spine，LLC、SpinTech MRI，Inc.、CPD to SPD，LLC、Culture（MD）Holdings，LLC和Genesis Investment Holdings的董事。他在阿尔比恩学院获得经济和管理文学士学位。
- Matthew Ahearn,has served as Shoulder Innovations Chief Operating Officer since October 2020 and a member of Shoulder Innovations board of directors since February 2017. Prior to this role, Mr. Ahearn was Shoulder Innovations Chief Executive Officer and President from February 2017 to October 2020 and Shoulder Innovations Chief Financial Officer and Chief Operating Officer from November 2020 to September 2023. Mr. Ahearn also currently serves as a director for HAPPE Spine, LLC, SpinTech MRI, Inc., CPD to SPD, LLC, cultivate(MD) Holdings, LLC, and Genesis Investment Holdings. He received a Bachelor of Arts in Economics and Management from Albion College.
- David L. Blue
David L. Blue，自2023年10月起担任Shoulder Innovations首席客户体验官，此前曾于2017年5月至2023年10月担任Shoulder Innovations首席商务官。2017年5月至2021年10月，Blue先生担任Genesis Innovation的销售与营销总监、副总裁，并于2013年7月至2017年5月担任Conventus Orthopedics的首席商务官。自2018年1月起，Blue先生还担任Cultivation（MD）Capital Funds的董事会成员，目前担任Cultivation（MD）Holdings，LLC的董事。他获得了奥古斯塔纳大学的工商管理和市场营销文学学士学位。
David L. Blue,has served as Shoulder Innovations Chief Customer Experience Officer since October 2023 and previously served as Shoulder Innovations Chief Commercial Officer from May 2017 to October 2023. From May 2017 to October 2021, Mr. Blue served as Director, VP, Sales & Marketing at Genesis Innovation and as Chief Commercial Officer at Conventus Orthopedics from July 2013 to May 2017. Since January 2018, Mr. Blue has also been a member of the board of directors of cultivate(MD) Capital Funds and currently serves as a director of cultivate(MD) Holdings, LLC. He received a Bachelor of Arts in Business Administration and Marketing from Augustana University.- David L. Blue，自2023年10月起担任Shoulder Innovations首席客户体验官，此前曾于2017年5月至2023年10月担任Shoulder Innovations首席商务官。2017年5月至2021年10月，Blue先生担任Genesis Innovation的销售与营销总监、副总裁，并于2013年7月至2017年5月担任Conventus Orthopedics的首席商务官。自2018年1月起，Blue先生还担任Cultivation（MD）Capital Funds的董事会成员，目前担任Cultivation（MD）Holdings，LLC的董事。他获得了奥古斯塔纳大学的工商管理和市场营销文学学士学位。
- David L. Blue,has served as Shoulder Innovations Chief Customer Experience Officer since October 2023 and previously served as Shoulder Innovations Chief Commercial Officer from May 2017 to October 2023. From May 2017 to October 2021, Mr. Blue served as Director, VP, Sales & Marketing at Genesis Innovation and as Chief Commercial Officer at Conventus Orthopedics from July 2013 to May 2017. Since January 2018, Mr. Blue has also been a member of the board of directors of cultivate(MD) Capital Funds and currently serves as a director of cultivate(MD) Holdings, LLC. He received a Bachelor of Arts in Business Administration and Marketing from Augustana University.